<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500812</url>
  </required_header>
  <id_info>
    <org_study_id>BA-210-101</org_study_id>
    <nct_id>NCT00500812</nct_id>
    <nct_alias>NCT00104221</nct_alias>
  </id_info>
  <brief_title>A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries</brief_title>
  <official_title>A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, open-label, dose-escalation study designed to evaluate the
      safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury
      patients: those with a complete cervical injury or a complete thoracic injury. Dose levels
      from 0.3 mg - 9 mg of Cethrin will be administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary goal of this study is to determine the safety and tolerability of Cethrin when administered in conjunction with fibrin sealant to the dura mater of the spinal cord.</measure>
    <time_frame>Prestudy, 24-72 hrs, 6 weeks, 3, 6 &amp; 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy by AIS</measure>
    <time_frame>Pre-study, 24-72 hrs, 6 weeks, 3, 6 &amp; 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects Receiving 0.3 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 3 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 6 mg Cethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 9 mg Cethrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cethrin</intervention_name>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_label>1 mg</arm_group_label>
    <arm_group_label>3 mg</arm_group_label>
    <arm_group_label>6 mg</arm_group_label>
    <arm_group_label>9 mg</arm_group_label>
    <other_name>(BA-210)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be enrolled in this study only if they meet all of the following criteria:

          -  Informed Consent Form signed by the patient or patient's legal representative.

          -  Male or female, aged 16-70 years, inclusive.

          -  For Group 1, patients with acute thoracic (T2-T12) spinal cord injury; for Group 2,
             patients with acute cervical (C4-T1) spinal cord injury. The site of surgery should be
             able to accommodate a minimum volume of 2 mL of fibrin sealant.

          -  Scheduled to undergo spinal decompression surgery or other interventional spinal
             surgery (e.g., fixation) within 7 days of injury.

          -  ASIA Impairment Scale grade of A (complete, no motor or sensory function present in
             the sacral segment) as assessed within 12 hours before surgery.

          -  Able to communicate effectively to obtain informed consent and to ensure neurological
             examination.

        Exclusion Criteria:

        Patients will not be enrolled in this study if they meet one of the following criteria:

          -  Use of any experimental drug, or participation in any clinical trial, within 30 days
             prior to surgery.

          -  History of adverse reaction to fibrin sealant.

          -  History of hypersensitivity to bovine products.

          -  Any medical condition that may interfere with the ASIA assessments.

          -  Clinically significant neurological, cardiac, respiratory, hepatic, or renal disease
             or malignancy.

          -  Hemophilia or other bleeding abnormality as defined by:

               -  Platelet level lower than 100 X 109/L

               -  Activated partial thromboplastin time or international normalized ratio higher
                  than the upper limit of normal

               -  Baseline hematocrit lower than 0.25

          -  Gunshot wound as the presenting injury, or any evidence of transecting injury to the
             spinal cord (e.g., by stab wound).

          -  Cognitive impairment which may preclude accurate neurological assessments (e.g.
             traumatic head injury with GCS of less than or equal to 14).

          -  Ankylosing Spondylitis.

          -  Diabetes mellitus requiring insulin therapy.

          -  Known immunodeficiency, including Acquired Immune Deficiency Syndrome or use of
             immunosuppressive or cancer chemotherapeutic drugs.

          -  Pregnancy or breastfeeding during the study. A serum pregnancy test will be performed
             at Screening for female patients of childbearing potential. In addition, patients who
             are considered likely to be pregnant may be excluded at th Investigator's discretion.

          -  Any condition or situation likely to cause the patient to be unable or unwilling to
             participate in study procedures or participate in all scheduled study assessments,
             including follow up through Month 6.

          -  Any condition likely to result in the patient's death within the next 6 Months.

          -  Any other condition that, in the opinion of the Investigator, would preclude the
             patient's participation in the study.

          -  Previous participation in this study.

          -  Use of intravenous heparin in previous 48 hours, thrombolytics and/or aspirin
             containing products in the previous 10 days.

          -  Non-traumatic causes of spinal cord injury (e.g. transverse myelitis, acute disc
             herniation, etcâ€¦).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Fehlings, MD, PhD, FRCSC, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univestity Health Network, Toronto Western</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Mayfield Clinic and Spine Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrooke Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bioaxonebio.com</url>
    <description>Sponsor</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=mckerracher%20Fehlings</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>McKerracher L, Anderson KD. Analysis of recruitment and outcomes in the phase I/IIa Cethrin clinical trial for acute spinal cord injury. J Neurotrauma. 2013 Nov 1;30(21):1795-804. doi: 10.1089/neu.2013.2909. Epub 2013 Oct 1.</citation>
    <PMID>23844986</PMID>
  </results_reference>
  <results_reference>
    <citation>Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CI, Kwon BK, Chapman J, Yee A, Tighe A, McKerracher L. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96. doi: 10.1089/neu.2011.1765.</citation>
    <PMID>21381984</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2007</study_first_posted>
  <disposition_first_submitted>March 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biologic drug</keyword>
  <keyword>transport sequence</keyword>
  <keyword>rho</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>paralysis</keyword>
  <keyword>paraplegia</keyword>
  <keyword>tetraplegia</keyword>
  <keyword>quadraplegia</keyword>
  <keyword>trauma</keyword>
  <keyword>nervous system</keyword>
  <keyword>fibrin sealant</keyword>
  <keyword>neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

